Catalent Pharma Solutions, global provider of advanced delivery technologies and development solutions, has announced it will adopt digital cell biology company — Berkeley Lights’ — Beacon optofluidic platform to accelerate its cell line development workflow.
collaboration
The Beacon platform, which is ideally suited for cell line development, antibody discovery (including direct B-cell workflows), gene editing and antibody engineering workflows, has the ability to screen thousands of clones in parallel. Therefore, automating cell line development with this platform will enable an increase in efficiency and faster identification of the top producing clones as well as providing additional insights into the behaviour of clonal populations that are currently unavailable with traditional techniques.
All four integrated workflows of the Beacon platform — import, culture, assay and export — will be applied to Catalent Biologics’ GPEx cell line development platform, in addition to the company’s ongoing research and development activities.
“Catalent has a history of applying advanced technologies to provide a differentiated offering to our customers,” said Mike Riley, vice president and general manager of Drug Substance and Bioanalytical services for Catalent Biologics. “Implementing the Beacon platform for cell line development has the potential to significantly accelerate our customers’ development timelines and bring more transformational biologic therapeutics to patients.”
“We are delighted to be working with Catalent and share their vision of speeding timelines and increasing efficiencies for customers,” added Andy Last, chief commercial officer at Berkeley Lights. “The value that the Beacon platform creates for the biopharmaceutical market can be seen with its rapid adoption. Today, approximately 50% of the top 25 biopharmaceutical companies have implemented the Beacon platform for one or more workflows, and we’re excited that Catalent Biologics is the first technology and service provider to launch the platform in North America.”